ALN-TTR02

3 Promising Stocks Targeting CTGF and Dermal Scarring
Wall St Cheat Sheet
Sat, 09/14/13 - 10:56 am
dermal scarring
RXI-109
Alnylam
Pfizer
RXi Pharmaceuticals
EXC-001
ALN-TTR02
Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)
Yahoo/BusinessWire
Sun, 06/30/13 - 10:42 am
ALN-TTR02
Alnylam
amyloidosis
TTR-mediated amyloidosis
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
TheStreet.com
Fri, 06/7/13 - 08:41 am
Zerenex
Xoma
Vical
Takeda
sovaprevir
Soluble Ferric Pyrophosphate
Rockwell Medical
Orexigen
MM-398
Merrimack Pharmaceuticals
MannKind
Keryx
GTx
GSK
gevokizumab
enobosarm
Coronado Biosciences
Contrave
CNDO-201
clinical trials
ChemoCentryx
CCX140
Biodel
BIOD-123
Amigal
Amicus Therapeutics
Alnylam
ALN-TTR02
Allovectin
Afrezza
Achillion
ACH-3102
2 Biotech Stocks To Consider This Week In The Wake Of Trial Data
Seeking Alpha
Thu, 12/13/12 - 11:33 am
Celldex
Alnylam
rindopepimut
ALN-TTR02
RNAi
Alnylam Pushes Forward In Amyloidosis After Pfizer Setback
Seeking Alpha
Tue, 07/17/12 - 11:08 am
Alnylam
amyloidosis
Pfizer
ALN-TTR02
Alnylam soars 31% on drug study
Marketwatch
Mon, 07/16/12 - 12:21 pm
Alnylam
ALN-TTR02
TTR-mediated amyloidosis
Alnylam gets orphan status for drug candidate
Yahoo/AP
Tue, 06/19/12 - 04:43 pm
Alnylam
orphan drugs
ALN-TTR02
Alnylam initiates Phase II study of ALN-TTR02
Pharmaceutical Business Review
Sat, 06/9/12 - 04:42 pm
Alnylam
ALN-TTR02
amyloidosis